Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Boston Therapeutics Inc (OTCQB:BTHE)

0.11
Delayed Data
As of Sep 02
 0.00 / 0.00%
Today’s Change
0.08
Today|||52-Week Range
0.80
-83.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$4.3M

Company Description

Boston Therapeutics, Inc. is a pharmaceutical company, which engages in the development, manufacture, and commercialization of novel compounds based on complex carbohydrate chemistry. Its products include therapeutic modules such as BTI320, Ipoxyn, and Oxyfex. The company was founded by David Platt and Kenneth A. Tassey Jr. on August 24, 2009 and is headquartered in Manchester, NH.

Contact Information

Boston Therapeutics, Inc.
1750 Elm Street
Manchester New Hampshire 03104
P:(603) 935-9799
Investor Relations:
(603) 512-6593

Employees

Shareholders

Individual stakeholders42.33%
Mutual fund holders--
Other institutional--

Top Executives

David PlattChairman, Chief Executive Officer & Treasurer
Louise GelinasDirector-Business Operations
Anthony Don SquegliaCFO, Secretary & Vice President-Investor Relations
Benjamin RivnayChief Scientist
Eric HobermanManager-Clinical Affairs